Analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a research note issued to investors on Saturday. The firm set a “hold” rating on the stock.
Separately, HC Wainwright decreased their price target on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Monday, August 12th.
Get Our Latest Research Report on ONCT
Oncternal Therapeutics Price Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.14. The business had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. During the same quarter last year, the company posted ($3.00) earnings per share. As a group, analysts expect that Oncternal Therapeutics will post -11.63 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Featured Stories
- Five stocks we like better than Oncternal Therapeutics
- Best Stocks Under $5.00
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- 5 discounted opportunities for dividend growth investors
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.